Danish enzyme maker Novozymes has spun out its biopharma activities into a new independent company called Albumedix.

Albumedix is 100% owned by Novozymes and will continue to focus on technologies and products based on recombinant albumin, a naturally occurring protein that can be found in human blood.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The recombinant albumins products, under Recombumin brand, are used in the pharmaceutical industry to stabilise drugs and vaccines.

Albumin can also be used to extend the half-life of pharmaceuticals to prolong the drugs’ effect, Novozymes said.

"We believe (the business) is now ready to be developed further outside Novozymes, where it will have the best possible growth conditions."

Albumedix offers a first and second generation version of this drug delivery technology under the name Veltis.

In 2014, GlaxoSmithKline launched a diabetes drug that utilises the Veltis technology to allow patients to dose weekly instead of daily.

Novozymes business development executive vice president Thomas Videbæk said: "Over the past nine years, our work in albumin has resulted in a series of new discoveries and technologies, which have led to agreements with major pharmaceutical and biotech companies.

"The business is in good shape with great prospects to make a real difference for patients all over the world. We believe it is now ready to be developed further outside Novozymes, where it will have the best possible growth conditions."

Albumedix will also begin exploring early stage clinical drug development based on its Veltis technology and relevant drug candidates.

Novozymes’ biopharma business head Peter Rosholm has been appointed as the CEO of Albumedix.

With headquarters in Lyngby, Denmark, Albumedix will have R&D and production facilities in Nottingham, UK, and will employ approximately 100 people.

"I see a promising future for Albumedix, and together with Don deBethizy and the rest of the team I look forward to expanding our role in the pharmaceutical industry.

"With our heritage, expertise in albumin, and skilled employees, we have a strong foundation for developing superior biotherapeutics for patients," added Peter Rosholm.